Background: The objective of the study was to compare a new AutoDELFIA ® Inhibin A kit (B064-102) with the Access Inhibin A kit (A36097) using clinical specimens and to evaluate the AutoDELFIA ® Inhibin A assay performance in screening for Down syndrome in the second trimester of pregnancy. Methods: Using clinical samples, we performed a method comparison between new and existing inhibin A kits and assessed AutoDELFIA ® Inhibin A kit precision performance. Normal median values for the second trimester of pregnancy were also determined. Finally, we evaluated the screening performance of the AutoDELFIA ® Inhibin A kit together with other second trimester biomarkers for the detection of Down syndrome.
Introduction
Inhibins are heterodimeric glycoproteins belonging to the transforming growth factor-β superfamily [1] , which were initially described for their suppression of follicle stimulating hormone secretion [2, 3] . They comprise a common α-subunit and one of two β-subunits, βA and βB, linked by disulfide bridges. These give rise to two fully processed 32 kDa dimeric inhibins, namely inhibin A and inhibin B [4, 5] . These hormones are secreted by the granulosa cells of the ovary in females, sertoli cells of the testis in males, and also the foetoplacental unit throughout pregnancy. During pregnancy, inhibin A is the major molecular form in the maternal circulation. Concentrations initially peak at 8 weeks' gestation then steadily decrease up to 16 weeks. After remaining relatively constant during second trimester weeks 15-18, levels increase again during the third trimester to reach a peak concentration at 36 weeks [5] [6] [7] .
From around 1992, publications started to emerge investigating inhibin as a potential marker in screening for Down syndrome. Non-specific methods for inhibin using antibodies directed towards the α-subunit were initially studied, yielding variable Down syndrome screening performance results [8, 9] . However, the subsequent development of a monoclonal antibody pair, measuring inhibin A specifically, resulted in many studies showing elevated levels in the late first trimester and early second trimester in women with a fetus affected by Down syndrome [7, [10] [11] [12] [13] [14] [15] [16] , thus indicating its potential clinical utility in Down syndrome screening. As a result of the gradual maturation of this assay [17] , inhibin A measurement was introduced into second trimester antenatal screening for aneuploidies in the late 1990s, resulting in what is now often referred to as the 'Quad Test'. This four-marker protocol, also including measurement of human alpha foetoprotein (hAFP), free beta subunit of human chorionic gonadotropin (free hCGβ), or hCG and unconjugated oestriol (uE3), has been reported to achieve a detection rate (DR) of up to 81% with a false positive of 5% [18, 19] .
Currently the Access Inhibin A kit (Beckman Coulter, Inc., Brea, CA, USA) is the only automated inhibin A assay in clinical use. In this study, we compare results obtained from the new AutoDELFIA ® Inhibin A kit (PerkinElmer, Turku, Finland) to that of the Access Inhibin A kit using second trimester clinical specimens. Furthermore, we establish medians for unaffected pregnancies in different gestational weeks during second trimester of pregnancy. Finally, we investigate the screening performance of AutoDELFIA ® Inhibin A kit in screening of Down syndrome during second trimester of pregnancy in combination with markers hAFP, free hCGβ, and uE3, or hAFP and free hCGβ.
Materials and methods

Study specimens
Second-trimester maternal serum samples were collected from women attending routine screening procedures for chromosomal abnormalities at King George Hospital Antenatal Clinic, London, UK. To meet the inclusion criteria in this study, the maternal blood sample must have been taken between gestational weeks 14 and 20+6 of pregnancy and maternal age must be ≥ 18 years at blood sample collection. Gestational age was determined by ultrasound (crown-rump length, biparietal diameter or head circumference). Excess serum was stored at −20 °C or colder with ethical approval (NRES Committee East Midlands -Nottingham 1 application 14/EM/1229) and patient consent for the sample to be used for research.
All samples were collected between June 2002 and December 2014. Serum samples used for method comparison were collected between April 2011 and November 2014. Single and multiple pregnancies were included in the method-comparison study. The samples used for median equation determination were collected between January 2013 and December 2014. Multi-foetal pregnancy samples were excluded from this median study. In the screening performance evaluation, for each case of Down syndrome, four to six control samples were matched according to sample storage time (±12 months) and other underlying factors affecting marker concentrations [e.g. gestational age (±3 days), maternal race or ethnic origin, smoking (yes or no) and number of freeze-thaw cycles (±1)]. Although sample stability of inhibin A is sufficient for screening purposes [20] , there are indications that long-term storage of inhibin-related molecules might have an effect on measured concentration levels [21] and that is why the storage-time matching was also included. For the precision study, the samples were provided by PerkinElmer and were prepared by diluting serum obtained from a pregnant woman with non-pregnant serum in different ratios to obtain the selected concentrations. Serum used for preparation of precision samples was anonymised leftover serum collected after signed consent form and under approval from the Ethics Committee of The Hospital District of Southwest Finland. Also the Maternal Screening Controls (Randox Laboratories, Crumlin, UK), normally used for quality control, that are prepared from human serum, were considered as precision study samples.
Inhibin A assay
The new, fully automated AutoDELFIA ® Inhibin A kit (B064-102) is a solid phase, two-site fluoroimmunometric assay based on the direct sandwich technique in which two mouse monoclonal antibodies are directed against two separate antigenic determinants on the dimeric inhibin A molecule. The following analytical characteristics are from the kit-specific insert and verified by the manufacturer. Assay measuring range and performance characteristics (LoD and LoQ), defined according to CLSI guidelines EP05 [22] and EP06 [23] , are from 8.0 pg/mL to 2000 pg/mL, 5.7 pg/mL and 6.3 pg/mL, respectively. The total variation of the AutoDELFIA ® Inhibin A assay, determined using serum samples, three kit lots and three AutoDELFIA ® instruments over 27 days, at the levels of 39.3, 215 and 1110 pg/mL is 5.7%, 4.0% and 3.7%, respectively. Calibration of the kit can be traced to WHO International Standard, NIBSC code: 91/624 (National Institute for Biological Standards and Control, South Mimms, UK).
The studies described in this article (method comparison, precision, medians and clinical performance evaluation) were performed using one kit lot.
Calibration and quality control
Calibration for all assays was carried out as described in the respective kit inserts. For all AutoDELFIA ® Inhibin A kits, this involved a full calibration curve run on each plate in duplicate. AutoDELFIA ® assay QCs were run twice per plate in singlicate (right after the calibrators and again after the specimens). For Access assays, quality controls were analysed according to the study protocol, i.e. twice daily.
Site-specific QC mean values were established prior to analysing the samples. For Inhibin A, this involved running QCs (AutoDELFIA: Maternal Screening Control levels 1-3, Randox Laboratories, Crumlin, UK; Access: Access Inhibin A QC, A36100, Beckman Coulter, Inc., Brea, USA) in quadruplicate on both devices (AutoDELFIA and Access) over a period of 5 days. A maximum of two runs per day were separated by a minimum of 2 h. The total amount of runs was six giving a total of 24 results per QC level.
Method-comparison study
Method-comparison studies were performed using a total of 175 specimens, of which 153 were maternal serum collected from frozen storage and 22 were spiked serum samples (provided by PerkinElmer) used to cover the kit measuring range 8-2000 pg/mL. The sample size was based on the requirement in the CLSI guideline EP09 [24] .
The study specimens were analysed in singlicate over 7 operating days using both the AutoDELFIA ® Inhibin A (B064-102) and Access Inhibin A (A36097) methods. All reagents were used according to the manufacturers' procedures described in the package inserts. Regression analysis was performed with weighted Deming-regression, which adjusts for the proportional variation of results. The correlation between methods was assessed with a Pearson correlation coefficient and for comparison with a Spearman correlation coefficient as the data did not follow a normal distribution. A Bland-Altman plot was also generated. Statistical analysis was done using Analyse-it 2.30 for Microsoft Excel (Analyse-it Software Ltd, Leeds, UK).
Precision study
The precision study for the AutoDELFIA ® Inhibin A kit was conducted over 5 days. Three pregnancy serum samples and maternal screening control levels 1-3, which were also used as run controls, were assayed. One run per day, five replicates per sample and control in each run were conducted resulting in 25 results per sample. The order of the samples and controls within precision plates were randomised and changed between different runs. Statistical analysis was done using Spotfire S+ version 8.1 (TIBCO Spotfire, Boston, MA, USA).
The within-lot precision can be expressed as
where σ WiRun = within-run standard deviation, n = number of replicate samples within run (for singlicate n = 1), σ BwRun = standard deviation between runs (days).
Median and screening performance study
Determination of normal median values for second trimester of pregnancy was done by running 346 serum samples, approximately 50 samples per gestational week. Screening performance characteristics for the AutoDELFIA ® Inhibin A kit were assessed in combination with AutoDELFIA ® uE3 (PerkinElmer, Turku, Finland) to complete the QUAD screening panel. Additionally, KRYPTOR hAFP and KRYPTOR Free β-hCG assays (Thermo Fisher Scientific, BRAHMS, Hennigsdorf, Germany) were used during routine screening procedures and results from these assays were also used in the analysis.
Specimens were analysed in singlicate in a random order over 13 operating days using AutoDELFIA ® Inhibin A and AutoDELFIA ® uE3 kits so that each run contained specimens from different gestational weeks and cases were also dispersed. Statistical analysis was done using Spotfire S+ version 8.1 (TIBCO Spotfire, Boston, MA, USA). Figure 1 compares the AutoDELFIA ® and Access Inhibin A measurements from 152 serum samples in a scatter plot ( Figure 1A ) and Bland-Altman plot ( Figure 2B ). For one sample, the relative difference between the methods was 258% which exceeds the limit of 83.6% (overall average×4). Thus, the sample was concluded to be an outlier and was excluded from further statistical analysis based on EP09 [24] .
Results
Method comparison
For all the data (maternal and spiked samples), the average relative difference between the two methods was 19.6% (95% CI, 17.6%-21.5%). Similarly, when only considering maternal sample results (n = 152), the average relative difference was 20.4% (95% CI, 18.7%-22.2%). The Bland-Altman test, which evaluates difference over the mean of all test results rather than against comparator Acceptance limit, derived from product specification, for within-lot variation was CV%, < 7%.
(including spiked samples) covering the whole range 41.7-1925 pg/mL, the observed correlations was 0.97 (Pearson correlation) and 0.99 (Spearman correlation).
Precision study
Study acceptance criteria were based on within-lot precision with limits taken from the product specification (CV%, < 7% for concentration above 30 pg/mL).
The individual variation components of within-lot variation were calculated by fitting a hierarchical linear random model (a nested model II ANOVA) separately for each sample level. These cleared variance components were used to calculate the within-lot variation component. Table 1 shows the precision results of the AutoDEL-FIA ® Inhibin A assay. The within-lot variation verified by the manufacturer at the levels of 39.3, 215 and 1110 pg/mL are 4.8%, 3.3% and 3.3%, respectively. Maximum  5th percentile  95th percentile   14   53  247  112  987  133  519  15   48  201  109  437  134  395  16   51  193  91  601  102  444  17   50  211  111  524  132  436  18   50  204  87  481  123  363  19   55  224  89  557  132  399  20   39  248  77  618  89  450  Total   346  214  77  987  119 
Median and screening performance study
Discussion
A new, fully automated AutoDELFIA ® Inhibin A assay was evaluated for clinical use in second trimester screening of Down syndrome. Method-comparison studies indicated A second order polynomial regression equation was found to be a good fit for inhibin A as a function of gestation day. The fitted regression model was 10ˆ(4.95206− 0.04297×gestation day+0.000175×gestation day 2 ). Analyte concentration values, converted to multiple of median (MoM) values, were used in a multivariate Gaussian model based risk calculation. For the analytes that were not run in this study (free hCGβ and hAFP), the MoM values were obtained from the study-site database which were already corrected for maternal weight, ethnicity, smoking and gestational age. For the analytes that were run in this study (inhibin A and uE3), the gestational age median equations based on study data were calculated and compared to the default equations in LifeCycle 4.0 (PerkinElmer, Turku, Finland). For inhibin A, the equation established in this study was considered appropriate and therefore used in the risk calculation. The shape of the median curve was identical to that of the default equation in LifeCycle 4.0 (based on a large screening data set) but it was offset at a different concentration level, which was in line with the results of the methodcomparison study.
The gestational age-adjusted MoM values were calculated using the study-specific median equation for inhibin A and the LifeCycle 4.0 default median equation for uE3. These MoM values were further adjusted by maternal weight, ethnicity and smoking status using LifeCycle default correction factors. For free hCGβ and hAFP, the existing MoM values from routine screening were used. Final MoM values were used in the LifeCycle 4.0 risk calculation software to obtain risk values for samples in the case-control dataset. In the risk calculation, the default population parameters were used (affected and unaffected means, standard deviations, correlations and truncation limits).
The value of inhibin A in screening for Down's syndrome was evaluated by calculating DRs with fixed false positive rates (FPRs) and FPR with fixed DR using different combinations of markers in risk calculation. The following combinations were used and the value of inhibin A was assessed by comparing calculations with the respective combinations without inhibin A.
-Inhibin A+free hCGβ+hAFP+uE3 -Inhibin A+free hCGβ+hAFP Tables 3 and 4 show that addition of inhibin A in the risk calculation gives improved screening performance with both combinations. In addition to calculations of DR and FPR, receiver operating characteristics (ROC) curves were plotted, to compare the calculations with and without inhibin A (Figure 2) . Area under the curve 19 .6% higher than the Access assay; a difference which could be attributed to different properties of two compared kits, e.g. components, assay kinetics and incubation times. However, since screening laboratories define their own assay-specific and gestational age-specific median values and report results as multiple of the medians, this mild discrepancy is not clinically important.
Results in
In the precision study, six samples of different levels from the clinically relevant range were assayed with the AutoDELFIA ® Inhibin A over 5 days. The results showed that all the precision samples were clearly in the acceptable level as the within-lot CV% varied from 1.9% to 3.9%. Overall the kit precision was excellent on all sample levels. There are external quality assurance programs (e.g. UKNEQAS) which provide quality-control samples for inhibin A monitoring, and these programs will be implemented also to cover the new AutoDELFIA ® Inhibin A assay.
Inhibin A medians in the second trimester of pregnancy (n = 346, weeks [14] [15] [16] [17] [18] [19] [20] were established in pregnancy unaffected by Down syndrome and used in subsequent risk calculations. The derived median equation was similar in shape as the existing median equation in the LifeCycle 4.0 risk calculation software, but it was higher in concentration, which was in accordance with the method-comparison study. The median equation for the AutoDELFIA ® Inhibin A assay was also generated in two different laboratories (data not shown) and those equations were highly similar (in shape and level) to the one generated in this study.
In order to demonstrate the performance of AutoDELFIA ® Inhibin A assay in screening for Down syndrome, risk calculations were carried out using different combinations of markers, i.e. hAFP, free hCGβ and uE3 or hAFP and free hCGβ with and without inhibin A. Based on the high correlation coefficient between the assays, we decided to use the existing population distribution parameters as this relatively small sample set was not sufficient to generate study-specific parameters. In agreement with the published literature, the addition of inhibin A improved the DR with all combinations studied and FPR of screening was reduced [19] . Larger, preferably prospective studies are advisable to confirm the clinical validity of the AutoDELFIA ® Inhibin A assay. In conclusion, in a technical comparison the AutoDELFIA ® Inhibin A assay yields comparable analytical results to an existing assay, whose clinical performance has been established. A retrospective casecontrol study confirmed that inhibin A, measured with the new AutoDELFIA ® Inhibin A kit, improves Down syndrome screening performance when added to a combination of two or three other second trimester serum markers.
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